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Abstract
Background: Malaria continues to be a significant health problem in India. Several of the intended Plasmodium
falciparum vaccine candidate antigens are highly polymorphic. The genetic diversity of P. falciparum merozoite
surface protein-1 (MSP-1) has been extensively studied from various parts of the world. However, limited data are
available from India. The aim of the present study was a molecular characterization of block 2 region of MSP-1
gene from the tribal-dominated, forested region of Madhya Pradesh.
Methods: DNA sequencing analysis was carried out in 71 field isolates collected between July 2005 to November
2005 and in 98 field isolates collected from July 2009 to December 2009. Alleles identified by DNA sequencing
were aligned with the strain 3D7 and polymorphism analysis was done by using Edit Sequence tool (DNASTAR).
Results: The malaria positivity was 26% in 2005, which rose to 29% in 2009 and P. falciparum prevalence was also
increased from 72% in 2005 to 81% in 2009. The overall allelic prevalence was higher in K1 (51%) followed by
MAD20 (28%) and RO33 (21%) in 2005 while in 2009, RO33 was highest (40%) followed by K1 (36%) and MAD20
(24%).
Conclusions: The present study reports extensive genetic variations and dynamic evolution of block 2 region of
MSP-1 in central India. Characterization of antigenic diversity in vaccine candidate antigens are valuable for future
vaccine trials as well as understanding the population dynamics of P. falciparum parasites in this area.
Background
Madhya Pradesh (MP) is situated in the central part of
India, and is a highly malarious state contributing 9% of
all malaria cases in the country [1]. Plasmodium falci-
parum infection has dramatically increased in MP in
recent years and is associated with life-threatening com-
plications in both children and adults [2,3].
The merozoite surface protein-1 (MSP-1) is a leading
vaccine candidate antigen. It is the most abundant sur-
face protein on the blood stage of P. falciparum, and it
is thought to play a role in erythrocyte invasion [4]. The
primary structure of MSP-1 is polymorphic and 40% of
the amino acid residues are different in different allelic
forms in P. falciparum [5]. The precursor of MSP-1 is a
protein comprising 1,720 amino acids, including a 20-
amino-acid signal sequence (SS) and a signal for anchor-
ing the protein at the cellular surface via a GPI moiety
(GA). MSP-1 divided into 17 blocks, which were either
variable, conserved or semi-conserved [6,7]. Sequences
of blocks 1, 3, 5, 12 and 17th are conserved, and blocks
2, 4, 6, 8, 10, 14 and 16 diverge extensively while in the
remaining blocks 7, 9 11, 13 and 15 are semi-conserved.
Variations in the sequences are dimorphic in nature
with the exception of polymorphic tripeptide encoding
region in block 2.
The block 2 region includes three allele families: K1,
MAD20, and RO33. Alleles in K1 and MAD20 contain
antigenically unique, tripeptide repeats, with extensive
diversity in the number of repeats [7]. RO33 lacks the
tripeptide repeats observed in the other two families;
however, outside block 2, this allele is similar to the
MAD20 type [8]. Fragment size in the three block 2
allele families has commonly been used as a molecular
marker in studies of malaria transmission dynamics and
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host immunity in P. falciparum malaria [9-13]. The pro-
tective immune responses have also been observed
against the motifs present in the major allele families of
block 2 and while the evidence suggests that the allele
families are maintained by selection, it is not clear how
selection operates against the number of tandem repeats
[14-16].
The purpose of this study was to explore the extent of
genetic variation in MSP-1 block 2 over the years in
central India for studying as a molecular marker in epi-
demiologic investigations, malaria transmission




The present study was carried out in Baigachak area of
Dindori district, Madhya Pradesh, India (Figure 1), from
July 2005 to November 2005 and July 2009 to December
2009 during peak transmission season. It is a highly
malarious district in the State of Madhya Pradesh with a
very high transmission rate [17]. Patients ranging
between one and 59 years of age presenting with fever
and symptoms of P. falciparum malaria were screened
for malaria parasites after obtaining consent. Fever his-
tory was obtained from the patient or by an accompany-
ing person (in the case of children). Physical
examination of the patients was performed and axillary
temperature recorded.
Sample collection
Parasitologic surveys were carried out to collect blood
smears from all fever cases and cases with history of
fever. Blood smears were stained with Jaswant Singh,
and Bhattacharji (JSB) stain examined under light micro-
scope for Plasmodium species identification [18].
Three to five drops of finger prick blood was blotted
on 3 MM filter paper (Whatman) to study genetic diver-
sity of MSP-1. Consent from the study subjects was
taken before collection the blood samples.
DNA isolation from filter paper
Blood spotted area was punched and put into a 1.5 ml
tube. The blood spot were soaked in 150 μl TE buffer
(10 mM Tris, 0.1 mM EDTA, pH 8.0) and incubated for
an hour at RT. After one hour incubation, tubes were
placed in dry bath at 50°C and incubated for 15 minutes
and punched by pipettes tips several times. Finally the
tubes were incubated at 97°C for 15 minutes and centri-
fuged at 8,000 rpm for 2 minutes. Supernatant was aspi-
rated and stored at -20°C for PCR amplification.
PCR amplification of the msp1 gene
The primary PCR was set up for the amplification of
block 2 region by using the primers MSP1A (forward):
5’-CACAATGTGTAACACATGAAAG-3’ and MSP1B
(reverse): 5’- AGTACGTCTAATTCATTTGCAC -3’.
The 646 bp primary PCR product was diluted 1:10 and
was used for the nested PCR. A nested PCR of a 555 bp
Figure 1 Map showing district Dindori, Madhya Pradesh, Central India.
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product was amplified by using the primers MSP1C(for-
ward): 5’ -TAGAAGCTTTAGAAGATGCAG-3’ and
MSP1 D(reverse): 5’ GACAATAATCATTAGCACA-
TAC 3’and sequenced. The primary PCR was performed
in a volume of 20 μL with 0.175 U of Taq DNA poly-
merase, 0.2 mM each dNTP, 0.4 μM each primer, and 1
mM MgCl2. The reaction was allowed to proceed for 35
cycles after an initial denaturation at 94 C for 1 minute,
annealing at 55 C for 1 minute, and extension at 72 C
for 1 minute. Final extension was at 72 C for 10 min-
utes. The nested PCR was performed with annealing at
53 C for 25 cycles. Other nested PCR conditions were
the same as those described for the primary PCR [17].
The PCR products were resolved on a 2% agarose gel.
Nucleotide sequencing
The PCR products were purified from the agarose gel by
using HyYeld™ gel/PCR DNA extraction kit (Real Bio-
tech Corp., Teipei Country, Taiwan), as per the manufac-
turer’s recommended protocol. From 200 to 250 ng of
the gel-purified product was used with the ABI Big Dye
Terminator Ready Reaction Kit Version 3.1 (PE Applied
Biosystems Foster City, CA 94404, USA) for the sequen-
cing PCR. The sequencing PCR was performed in a
volume of 20 μL with 1 μL to Terminator Ready Reaction
Mix (TRR), 3.2 pmol of gene specific primer MSP1C (555
bp of block 2 region) and 0.5X sequencing buffer. Cycling
conditions for the sequencing PCR included 25 cycles of
denaturation at 96 C for 10 seconds, annealing at 50 C
for 5 seconds, and extension at 60°CC for 4 minutes.
Templates were purified and sequenced on an ABI Prism
310 Genetic Analyzer (PE Applied Biosystems).
Sequence analysis
Sequence obtained was translated using the Edit
Sequence tool (DNASTAR). The translated sequences
were then aligned using the MEGALIGN program
(DNASTAR, INC., Madison, WI). Nucleotide sequences
are submitted to the GenBank database.
The expected heterozygosity was calculated by use of
the formula HE =
[
n/ (n− 1)]× [(1−pi2)], where n
is the number of samples and pi the frequency of allele
i. HE is the probability that two alleles randomly drawn
from the population sample are different. The mean
multiplicity of infection (MOI) was calculated as the
total number of clones divided by the number of posi-
tive samples for marker gene. Allele frequencies were
further compared between two year populations and P
value was calculated for significance.
Ethical approval
The study was approved by the Scientific Advisory
Committee, Ethical Committee of Regional Medical
Research Centre for Tribals, Jabalpur, MP, India and
informed consent and human subjects guidelines were
followed.
Results
The overall malaria positivity was 26% in 2005, which
rose to 29% in 2009 (Table 1) among the symptomatic
individuals. The P. falciparum prevalence was increased
from 72% in 2005 to 81% in 2009 {Odd ratio (OR) =
1.33 (1.0-1.77) and p < 0.05}.
Sequence polymorphism in block-2 of msp1
The 555 bp polymorphic region of block 2, merozoite
surface protein 1 gene was amplified. A total of 169 P.
falciparum infected blood samples from 2005 and 165
samples from 2009 were used for the amplification and
sequencing of merozoite surface protein 1, block 2. The
amplified fragments of 169 (71 from 2005, 98 from
2009) samples were sequenced and their sequences were
analysed with three alleles, K1, MAD20 and RO33.
Comparison of the sequences showed that all these iso-
lates belong to one of these three alleles. The overall
allelic prevalence was recorded which was higher in K1
(51%) followed by MAD20 (28%) and RO33 (21%) in
2005 while in 2009 RO33 was highest (40%) followed by
K1 (36%) and MAD20 (24%).
In the block 2 of MSP1, the nucleotide and the
deduced amino acid sequence were found to be highly
polymorphic among the isolates. All the nucleotide
changes in these isolates were non-synonymous, as a
result, the deduced amino acid variations corresponded
to one or other allele. A total 22 types of variants were
found in the K1 type alleles in 2005 and 21 types of var-
iants in 2009(Additional file 1: Figure S1). Out of these
21 variants only seven belong to 2005 types and the
remaining 14 were new variants (Figure 2). MAD20 type
of allelic had limited 11 variants in 2005 while in 2009
total 17 variants were found (Additional file 1: Figure
S2). Out of these 17 variants only five belong to 2005
types and the remaining 12 were new variants (Figure
3). The RO33 showed an almost semi-conserved pattern,
showing only two variants in 2005 samples but in 2009
(Additional file 1: Figure S3) it showed nine variants
(Figure 4).
Mean multiplicity of infection (MOI) was greater in
2009 than in 2005 for msp1 genes (msp1: 1.34 ± 0.44 vs.
1.27 ± 0.47; p > 0.05) Table 2. The frequencies of poly-
morphisms in polymorphic blocks 2, were compared
from 2005 to 2009 (Table 2). A significantly frequency
variation was observed in RO33 allelic family (GenBank
database accession numbers JF460898, JF460899,
JF460900, JF460901, JF460902, JF460903, JF460904,
JF460905, JF460906, JF460907, JF460908, JF460909,
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JF460910, JF460911, JF460912, JF460913, JF460914,
JF460915, JF460916, JF460917, JF460918, JF460919,
JF460920, JF460921, JF460922, JF460923, JF460924,
JF460925, JF460926, JF460927, JF460928, JF460929,
JF460930, JF460931, JF460932, JF460933, JF460934,
JF460935, JF460936, JF460937, JF460938).
Discussion
The genetic diversity of P. falciparum, msp1genes was
investigated from the field isolates of high transmission
area over the five-year periods from central India. Of
the 334 isolates, MSP1 sequencing was successfully
completed in 169 isolates.
Most malaria vaccine-candidate antigens are highly
polymorphic surface proteins that elicit variant specific
immunity. Therefore, the evolutionary relationships
could be explored for the design of vaccines based on
ancestral sequences, with the potential for including
cross-protection against a wide range of antigenic var-
iants. Thus, the understanding of mechanisms and
patterns of genetic recombination and sequence varia-
tion may help in designing a vaccine that represents the
worldwide repertoire of polymorphic malaria surface
antigens.
The MSP-1, with numerous alleles and differing in the
length of the genes, have been extensively studied and
their genetic polymorphisms were used to describe clon-
ality of infections in a large number of studies. Length
variability in MSP families is mainly results from repeat
sequences. The alleles of MSP-1 belong to the allelic
groups K1, MAD20 and RO33 with high variability
when comparing the groups, but less variability within
them. Minor amino acid diversity is created in malaria
parasite antigens by single-nucleotide replacement.
Dependent on the degree of amino acid substitution
(highly variable, semi-conserved, conserved), MSP-1 has
been categorized into 17 blocks [6]. Genetic recombina-
tions account for most variation seen in malarial anti-
gens, since it occurs in several orders of magnitude
more frequently than mutation [19]. Differential
Table 1 Malaria cases in study area with different age groups among symptomatic individuals
Study Year Age groups No. of Patients Screened No. of Positive Cases Pf Pv Mixed (Pf + PV) No. of Sample sequenced
2005 < 5 yr 128 31 23 6 2 16
5-15 yr 356 89 65 21 3 41
> 15 yr 169 49 33 13 3 14
2009 < 5 yr 118 40 30 8 2 23
5-15 yr 238 64 51 10 3 39
> 15 yr 221 61 53 7 1 36
Total 1230 334 255 65 14 169


































































Figure 2 Temporal variation in frequency distribution of K1 allelic family of Plasmodium falciparum msp1 haplotypes between 2005
and 2009 from study area. Frequencies are shown on the vertical axis and number of variants on X axis.
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prevalence of dimorphic MSP1 epitopes had previously
been reported by Conway et al. from West Africa (Gam-
bia and Nigeria) and Brazil (eastern Amazon) [20].
Block 2 is of particular interest, as it exhibits repetitive
tri-nucleotides and appears to be subjected to rapid intra-
genic recombination process, comparable to those of the
csp gene. It has been shown that IgG antibodies are
important in acquired anti-malarial immunity against the
most frequent subtypes of block 2 of MSP-1[15].
Previous studies of block 2 of MSP1 allelic types from
India yielded information of varying patterns of diversity
[21-23]. In the present study, results reveal that K1
alleles are dominant (51%) followed by MAD20 (28%)
and rest were RO33 type alleles in 2005 samples, in con-
trast to a Colombia study in 1990, where only MAD20
and RO33 type alleles were reported and the K1 type
alleles were missing. In Iran only limited numbers of K1
(7.6%) type alleles were reported by Mehrizi et al. [24].
Mahajan et al. reported all three types of alleles from
India [21]. In the Zambian isolates of MSP1 from
block2, 54% K types alleles, 35% RO33 and 11% of
MAD20 like alleles were reported [5]. Analysis of 2009
samples in present study showed 36% K types alleles,
40% RO33 and 24% of MAD20-like alleles.
In another study carried out in Choea (north-west




































































Figure 3 Temporal variation in frequency distribution of MAD20 allelic family of Plasmodium falciparum msp1 haplotypes between




































Figure 4 Temporal variation in frequency distribution of RO33 allelic family of Plasmodium falciparum msp1 haplotypes between 2005
and 2009 from study area. Frequencies are shown on the vertical axis and number of variants on X axis.
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were detected although MAD20 was the predominant
allele and K1 was less frequent [25]. The maximum var-
iation in this study (22 variants in 2005 and 21 variants
in 2009) was observed in the K1 allelic family. The
extensive variation in the repeat region of block 2 was
also reported by Tetteh et al. [5]. The highest variation
was observed in the high transmission area of Orissa
state, India by Ranjit and Sharma as compared to other
states of India [22]. Simultaneously, a high degree of
variation was recorded by Raj et al. in the high transmis-
sion area, as compared to the mesoendemic area in
Orissa state [23]. In the present finding, RO33 type
alleles were semi-conserved and only two variants were
found in 2005 samples and increased to nine by 2009.
The level of antigenic diversity of P. falciparum popu-
lations in an area is likely to affect acquisition of immu-
nity to malaria. Substantial variations in the prevalence
of block 2 alleles during different study period indicates
dynamic nature of msp1 genetic structure in P. falci-
parum populations. It is possible that acquisition of
strain specific immunity may modulate the selection of
different allelic variants and this may be one of the
explanation for the observed findings. Sequence analysis
of the present study identified numerous novel alleles
and specific motif arrangements of msp1, block 2 allele
sequences as reported by Escalante et al. [26]. Further
genetic polymorphism appear to evolve faster in the
higher transmission areas when compared to lower
transmission areas [27,28]. The degree of polymorphism
found in the present study is also consistent with the
high level of transmission of malaria in the study area as
reported previously by Singh et al., [29].
High level of MOI observed in this study fits with pre-
vious observations of an increased complexity of infec-
tion with increasing endemicity [30]. Over all findings
from this study indicates dynamic evolution of variation
in the msp1 gene of P. falciparum in the study area and
it could serve as a good marker in studying the P.
falciparum population in this region. In addition, exten-
sive genetic variation in the block 2 region of MSP-1
makes it as useful genetic markers in differentiating
parasite strains in clinical trials in this region.
Conclusion
The present study reports extensive genetic variations
and dynamic evolution of block 2 region of MSP-1 in
Central India. Characterization of antigenic diversity in
vaccine candidate antigens are valuable for future vac-
cine trials as well understanding the population
dynamics of P. falciparum parasites in this area.
Additional material
Additional file 1: Figure S1. Amino acid sequence alignment of the K1
allelic types of Plasmodium falciparum msp1 gene from central India.
Figure S2. Amino acid sequence alignment of the MAD20 allelic types of
Plasmodium falciparum msp1 gene from central India. Figure S3. Amino
acid sequence alignment of the RO33 allelic types of Plasmodium
falciparum msp1 gene from central India.
Acknowledgements
The authors gratefully acknowledge the support of the Indian Council of
Medical Research. We would like to thank Mr M P Singh for his assistance in
the study. Thanks are also extended to the patients who consented to
participate in this study.
Author details
1Regional Medical Research Centre for Tribals, Nagpur Road, Garha, Jabalpur
482003, Madhya Pradesh, India. 2National Institute of Malaria Research, Field
Station, Jabalpur, Madhya Pradesh, India. 3Department of Biotechnology, All
India Institute of Medical Sciences, New Delhi, India.
Authors’ contributions
PKB carried out PCR amplification, DNA sequencing experiments and drafted
the manuscript. MMS and PKB carried out patients’ enrolments, collected
clinical and epidemiological data and drafted the manuscript. YDS analysed
sequencing data and drafted the manuscript. NS conceived and designed
the study, monitor the field and laboratory experiments, analysed the data
and drafted the manuscript. All authors read and approved the final
manuscript.
Table 2 Genetic diversity of MSP1 from 2005 and 2009
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